1336963-95-1 Usage
Description
6-bromo-7-fluoroisatin is a heterocyclic compound characterized by the presence of a bromine atom at the 6th position and a fluorine atom at the 7th position in its molecular structure. It is known for its potential applications in the pharmaceutical and chemical industries due to its unique properties and reactivity.
Uses
Used in Pharmaceutical Industry:
6-bromo-7-fluoroisatin is used as a heterocyclic reagent for the synthesis of electrophiles that are capable of targeting K-Ras oncogene. This targeting is crucial in the treatment of various types of cancer, as the K-Ras oncogene is often mutated in several malignancies, leading to uncontrolled cell growth and tumor formation.
Used in Chemical Synthesis:
6-bromo-7-fluoroisatin is also utilized as a key intermediate in the synthesis of various chemical compounds, particularly those with potential applications in the pharmaceutical industry. Its unique structure allows for further functionalization and modification, enabling the development of new drugs and therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1336963-95-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,6,9,6 and 3 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1336963-95:
(9*1)+(8*3)+(7*3)+(6*6)+(5*9)+(4*6)+(3*3)+(2*9)+(1*5)=191
191 % 10 = 1
So 1336963-95-1 is a valid CAS Registry Number.
1336963-95-1Relevant articles and documents
Fused pyridone compounds as kinase inhibitors
-
, (2021/09/01)
The invention discloses a fused pyridone compound serving as a kinase inhibitor, and particularly discloses a compound represented by formula (I). The optical isomer and pharmaceutically acceptable salt thereof as well and as application of the compound as KRAS inhibitor.
Quinazoline compound and application thereof in medicine (by machine translation)
-
, (2020/08/22)
The invention relates to a quinazoline compound (shown in the formula I) and a medicinal salt thereof, which can be used for treating cancer. The invention also relates to a preparation method and a pharmaceutical composition containing the compounds. (by machine translation)
2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF
-
, (2017/06/12)
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5a, R5b, R6, A, G1, G2, L1, L2, m1, m2, n, X and E are as defined herein, and wherein at least one of R3a, R3b, R4a or R4b is not H. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
